TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percent of Women Who Show a Greater Than 50% Decline in Average Daily Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportions of women reaching desirable 25(OH)D level ≥20ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infant bone mineral content (BMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success rate of IAN Block anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Apparent volume of distribution-V
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin D blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vitamin D Intake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Students Stress Levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child Behavior Checklist (CBCL)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impact of episodic breathlessness on daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Composite Endpoint of CV Death, MI or Ischemic Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Composite Endpoint of CV Death or Hospitalization Due to Heart Failure
Endpoint domain: Mortality/survival
Primary endpoint: Walking Index for Spinal Cord Injury (WISCI II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge and Usage of Coping Strategies
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cumulative incidence of Major Adverse Cardiac Events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative incidence of Cerebrovascular Events (CVE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative incidence of Major Bleedings
Endpoint domain: Adverse events/effects
Primary endpoint: reduction in ischemia reperfusion injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the Modified Oswestry Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of 1 year Graft-Versus-Host Disease (GVHD) free
Endpoint domain: Mortality/survival
Primary endpoint: Rate of 1 year Graft-Versus-Host Disease (GVHD) relapse free survival
Endpoint domain: Mortality/survival
Primary endpoint: Energy excreted in feces and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak Inspiratory Flow Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum hemagglutination inhibition (HI) antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine levels post LPS challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change From Baseline in Global Ocular Discomfort Score at Day 71
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma pharmacokinetics of tranilast and methotrexate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of 12-Week CSBM Overall Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3, 4, and 5 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Pretest and posttest scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: best-corrected ETDRS visual acuity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Curative Intent Resection (R0) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: CV Death or Hospitalization for Heart Failure
Endpoint domain: Mortality/survival
Primary endpoint: Change in 25-hydroxyvitamin D (25(OH)D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Seven-day Point Prevalence Abstinence (Carbon Monoxide)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung ultrasound results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Measurement of the inferior vena cava
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gene expression levels in immune cells in salivary gland biopsy samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gene expression levels in immune cells in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gene expression levels in epithelial cells in salivary gland biopsy samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression levels in epithelial cells in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Total Body Clearance (Cl/f) of Unconjugated Rotigotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of Distribution at Steady State (VSS/f) of Unconjugated Rotigotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin-stimulated peripheral glucose disposal (Rd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased sputum neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Histologically complete resection (R0 resection)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean change in HbA1C from the baseline level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evaluation of the total daily time of plasma glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Responder Status at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed symptomatic proximal Deep Vein Thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mechanical Axis Alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Assessment of Cancer Therapy-Fatigue (FACT-F)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Cytokine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Tactile Sensitivity Score at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved frequency of recommended self-care behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: ECG Effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aggression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Posture and Postural Ability Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Segmental Assessment of Trunk Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of end-diastolic velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tinnitus Handicap Inventory Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Sneezing Symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Runny Nose Symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Stuffy Nose Symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Itching Symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Study Objective
Endpoint domain: General outcomes
Primary endpoint: Compliance as measured by the proportion of total sessions attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in dialyzer blood compartment volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability as assessed by the number of subjects with treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with unscheduled discontinuation of study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with HIV RNA<40 cps/ml at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Muscle strength in peak torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to onset of altered taste
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with any adverse experience
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean change in 2hr-postprandial glucose (PPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Suppression of appetite sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of appetite-related hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ketosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in average number of steps per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the color Trails Making Test part B
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Objective response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Density of the Total Hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Density of the Spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients survival or death
Endpoint domain: Mortality/survival
Primary endpoint: Rate of recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in complications at 72 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Global perception of usefulness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Responders' self-reported professional satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Permanently reduced lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Trough FEV1 Response at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mahler Transitional Dyspnea Index Focal Score at 24 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical benefit (CR, PR, stable disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of 18F-FDGal in the diagnosis of HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Autologous Expanded Mesenchymal Stem Cells transplantation
Endpoint domain: Adverse events/effects
Primary endpoint: successful aging scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Successful obstetric fistula repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adipose tissue function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cleanliness of the Prep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: injury complaint
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Social Phobia Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Successfully Desensitized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical Pain Score (NPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Daily Morphine Equivalents (MEQs)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Working Alliance Inventory (Short Form, Therapist)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Working Alliance Inventory (Client)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma Concentration of dexmedetomidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in CAFAS level of functioning
Endpoint domain: Life impact
Endpoint subdomain: Functional functioning
Primary endpoint: Total number of treatment related (serious) adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Nutritional quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum copper biomarker assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24-hour urinary copper concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Function of chemoport
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Success rate of resolution of triggering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of lung cancer diagnosed as stage I or II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with reactions and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who receive the vaccine who get immunity to shigella
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: one year graft survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Patients in Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of JNJ-39439335
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of JNJ-39439335
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCORAD - Scoring Atopic Dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Index of Itching Intensity and Scratching Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability and Feasibility Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: accuracy of volume assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom improvement post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in volume events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of Hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Fugl-Meyer during intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Motor Activity Log Quality Score during intervention
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Motor Activity Log Quantity Score during intervention
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma Leptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma Free Fatty Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Pemberton Happiness Index (PHI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Normal lung aging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Vaccinations Administered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Objective overall response proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Heart failure assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classic recognition score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classic fixation time faces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classic fMRI activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality of COVID-19 patients
Endpoint domain: Mortality/survival
Primary endpoint: Change in scores of Sexual Health Inventory for Men
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence Rate of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Loss of Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Loss of Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD response to various reward types
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD response at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral inhibitory control task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response of nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With at Least One Clinical Adverse Experience
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Discontinued Study Treatment Due to a Clinical Adverse Experience
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With at Least One Laboratory Adverse Experience
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Discontinued Study Treatment Due to a Laboratory Adverse Experience
Endpoint domain: Adverse events/effects
Primary endpoint: FCI Score at Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monitoring treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Weaning failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: African Palliative Care Association Palliative Outcome Scale (APCA POS) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in mindfulness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Connectedness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: EB viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: EBV-specific T cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Glutathione synthesis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrence Rate of AK-lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in remineralization of tooth decay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Exhaled Nitric Oxide (FeNO) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of recurrent hepatocellular carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: Percent Heavy Drinking Days During Active Treatment Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Propionibacterium Acnes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of CD27+ Switched Memory B Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total body vitamin A pool size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Standardised Uptake Value (SUV)Max at Day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Standardised Uptake Value (SUV)Max at Day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Asthma Action Plan knowledge (parent)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with epigenetic changes in histone modifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood oxygen level dependent (BOLD) signal activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes